New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 10, 2013
10:00 EDTAXAS, CHDN, APO, SEMG, TM, NFLX, IEP, HRB, MOFG, VRTX, ORC, RRMS, SBRA, PTSI, HOLX, NAVB, PDCE, SXL, HMC, IT, MWE, HTLFOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: H&R Block (HRB) initiated with an Outperform at Wedbush... Heartland Financial (HTLF) initiated with a Buy at DA Davidson... Hologic (HOLX) initiated with a Hold at Stifel... Icahn Enterprises (IEP) initiated with a Buy at Jefferies... MarkWest Energy (MWE) initiated with a Neutral at Goldman... Netflix (NFLX) initiated with an Underweight at Evercore... P.A.M. Transportation (PTSI) initiated with a Buy at Wunderlich... Gartner (IT) initiated with a Buy at Janney Capital... Netflix (NFLX) initiated with an Underweight at Evercore... Sabra Health Care (SBRA) initiated with a Buy at Sidoti... Honda (HMC) initiated with a Neutral at Guggenheim... Toyota (TM) initiated with a Buy at Guggenheim... Rose Rock Midstream (RRMS) initiated with an Equal Weight at Morgan Stanley... SemGroup (SEMG) initiated with an Overweight at Morgan Stanley... Orchid Island Capital (ORC) initiated with a Buy at Ladenburg... Sunoco Logistics (SXL) reinstated with an Outperform at Credit Suisse... Apollo Global (APO) initiated with a Market Perform at BMO Capital... PDC Energy (PDCE) initiated with a Hold at Topeka... Vertex (VRTX) initiated with a Buy at Chardan... Churchill Downs (CHDN) initiated with a Buy at Janney Capital... Navidea (NAVB) initiated with a Buy at Janney Capital... Abraxas Petroleum (AXAS) initiated with a Neutral at Global Hunter... MidWestOne (MOFG) initiated with a Neutral at DA Davidson.
News For HRB;HTLF;HOLX;IEP;MWE;PTSI;NFLX;IT;SBRA;TM;HMC;RRMS;SEMG;SXL;ORC;APO;PDCE;VRTX;CHDN;NAVB;MOFG;AXAS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
January 13, 2015
07:36 EDTVRTXVertex price target raised to $146 from $125 at Piper Jaffray
Piper Jaffray raised its price target for Vertex Pharmaceuticals shares to $146 citing continued Kalydeco growth after the company issued 2015 guidance. Piper reiterates an Overweight rating on Vertex.
07:29 EDTTMToyota to build three new plants, Reuters says
Subscribe for More Information
07:25 EDTTM, HMCNew NHTSA head says 2015 may see more recalls than record-setting 2014, WSJ says
Subscribe for More Information
06:49 EDTSBRASabra Health downgraded to Underperform from Market Perform at JMP Securities
Subscribe for More Information
06:30 EDTHMCHonda brings Acura NSX back after 10-year hiatus, WSJ reports
Subscribe for More Information
06:30 EDTPDCEPDC Energy initiated with a Hold at Deutsche Bank
Target $52.
January 12, 2015
16:36 EDTSBRASabra Health Care suspends issuing equity under ATM program
Subscribe for More Information
16:24 EDTSBRASabra Health Care sees FY15 FFO $2.19-$2.24, FY15 AFFO $2.05-$2.10
FY15 AFFO consensus $2.24. The company's guidance excludes the impact of investments that may be made during 2015 and reflects 59,047,001 shares of common stock outstanding as of December 31, 2014.
13:28 EDTMWEMarkWest Energy volatility near six-year high
Subscribe for More Information
10:00 EDTMWEOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:04 EDTNFLXAmazon wins first Golden Globe for 'Transparent,' Business Insider reports
Subscribe for More Information
08:18 EDTNFLXNetflix January weekly volatility elevated into Q4 and outlook
Subscribe for More Information
08:02 EDTHOLXHologic raises Q1 revenue to $653M from $625M-$635M, consensus $630.79M
Subscribe for More Information
07:35 EDTITNational Retail Federation to hold a trade show
Subscribe for More Information
06:31 EDTMWEMarkWest Energy downgraded to Neutral from Buy at Goldman
Subscribe for More Information
05:45 EDTMWEMarkWest Energy downgraded to Neutral from Buy at Goldman
Goldman Sachs downgraded MarkWest Energy to Neutral saying its reduced commodity price expectations no longer support an accelerating distribution growth profile for the company. The firm dropped its price target for shares to $64 from $78.
January 11, 2015
21:04 EDTVRTXVertex expects Q4 Kalydeco revenue $460M
Subscribe for More Information
21:03 EDTVRTXVertex sees 2015 Kalydeco revenue $560M-$580M
Vertex expects that its combined non-GAAP R&D and SG&A expenses in 2015 will be in the range of $1.05B-$1.1B. It said the increase as compared to 2014 is primarily a result of launch preparation activities for lumacaftor in combination with ivacaftor and the planned pivotal Phase 3 development program for VX-661 in combination with ivacaftor. Vertex's expected non-GAAP R&D and SG&A expenses exclude stock-based compensation expense and certain other expenses recorded in 2015. Vertex said entered 2015 with approximately $1.4B in cash, cash equivalents and marketable securities. Anticipated 2015 Kalydeco net revenues reflect: Use of KALYDECO by eligible patients in Australia following the completion of reimbursement discussions in late 2014; Use of KALYDECO in people in the United States with the R117H mutation following FDA approval in late 2014; The completion of reimbursement discussions for gating mutations in certain European countries; Use of KALYDECO in children with CF ages 2 to 5 with the G551D or other gating mutations in the United States, based on potential approval in March 2015.
21:00 EDTVRTXVertex says NDA for combination of lumacaftor, ivacaftor accepted by FDA
Subscribe for More Information
20:57 EDTVRTXVertex says NDA for ivacaftor use in children accepted by FDA
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use